Blood Pressure Management for Stroke Prevention and in Acute Stroke

키워드

참고문헌 (83)

1. WHO, "A global brief on hypertension" (2013), World Health Organization
2. O’Donnell MJ, "Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE):a case-control study", Lancet, 388, pp.761~775 (2016)
3. Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)
4. Lawes CM, "Blood pressure and cardiovascular disease in the Asia Pacific region", J Hypertens, 21, pp.707~716 (2003)
5. MacMahon S, "Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias", Lancet, 335, pp.765~774 (1990)
6. Rothwell PM, "Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study)", Lancet, 363, pp.1925~1933 (2004)
7. Carandang R, "Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years", JAMA, 296, pp.2939~2946 (2006)
8. Lackland DT, "Factors influencing the decline in stroke mortality: a statement from the American Heart Association", American Stroke Association, 2014, pp.45, 315~353
9. Kubo M, "Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study", Stroke, 34, pp.2349~2354 (2003)
10. James PA, "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)", JAMA, 311, pp.507~520 (2014)
11. Dong C, "Evidence to maintain the systolic blood pressure treatment threshold at 140 mm Hg for stroke prevention: the Northern Manhattan Study", Hypertension, 67, pp.520~526 (2016)
12. Psaty BM, "Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis", JAMA, 289, pp.2534~2544 (2003)
13. Law MR, "Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", BMJ, 338, pp.b1665~ (2009)
14. Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis", Lancet, 387, pp.957~967 (2016)
15. Hansson L, "Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study", Lancet, 354, pp.1751~1756 (1999)
16. Hansson L, "Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial", Lancet, 353, pp.611~616 (1999)
17. Brown MJ, "Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT)", Lancet, 356, pp.366~372 (2000)
18. Hansson L, "Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study", Lancet, 356, pp.359~365 (2000)
19. Dahlöf B, "Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol", Lancet, 359, pp.995~1003 (2002)
20. Dahlöf B, "Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trialblood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial", Lancet, 366, pp.895~906 (2005)
21. "Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group", JAMA, 283, pp.1967~1975 (2000)
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, "Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic:the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)", JAMA, 288, pp.2981~2997 (2002)
23. Jamerson K, "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients", N Engl J Med, 359, pp.2417~2428 (2008)
24. Matsuzaki M, "Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial", J Hypertens, 29, pp.1649~1659 (2011)
25. Grau AJ, "Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank", Stroke, 32, pp.2559~2566 (2001)
26. Kimura K, "Analysis of 16,922patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study", Cerebrovasc Dis, 18, pp.47~56 (2004)
27. Fonarow GC, "Characteristics, performance measures, and inhospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke", Circ Cardiovasc Qual Outcomes, 3, pp.291~302 (2010)
28. 김범준, "Case Characteristics, Hyperacute Treatment, and Outcome Information from the Clinical Research Center for Stroke-Fifth Division Registry in South Korea", 대한뇌졸중학회지, 17(1), pp.38~53 (2015), 대한뇌졸중학회
29. Carter AB, "Hypotensive therapy in stroke survivors", Lancet, 1, pp.485~489 (1970)
30. "Effect of antihypertensive treatment on stroke recurrence. Hypertension-Stroke Cooperative Study Group", JAMA, 229, pp.409~418 (1974)
31. "Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group", Stroke, 24, pp.543~548 (1993)
32. Eriksson S, "Atenolol in secondary prevention after stroke", Cerebrovasc Dis, 5, pp.21~25 (1995)
33. PATS Collaborating Group, "Post-stroke antihypertensive treatment study. A preliminary result", Chin Med J (Engl), 108, pp.710~717 (1995)
34. Liu L, "Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature", Hypertens Res, 32, pp.1032~1040 (2009)
35. PROGRESS Collaborative Group, "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105individuals with previous stroke or transient ischaemic attack", Lancet, 358, pp.1033~1041 (2001)
36. Rashid P, "Blood pressure reduction and secondary prevention of stroke and other vascular events:a systematic review", Stroke, 34, pp.2741~2748 (2003)
37. Yusuf S, "Telmisartan to prevent recurrent stroke and cardiovascular events", N Engl J Med, 359, pp.1225~1237 (2008)
38. Katsanos AH, "Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials", Hypertension, 69, pp.171~179 (2017)
39. Towfighi A, "Consistency of blood pressure control after ischemic stroke: prevalence and prognosis", Stroke, 45, pp.1313~1317 (2014)
40. Ovbiagele B, "Level of systolic blood pressure within the normal range and risk of recurrent stroke", JAMA, 306, pp.2137~2144 (2011)
41. Rothwell PM, "Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease", Stroke, 34, pp.2583~2590 (2003)
42. Chaturvedi S, "Risk factor status and vascular events in patients with symptomatic intracranial stenosis", Neurology, 69, pp.2063~2068 (2007)
43. Turan TN, "Rationale, design, and implementation of aggressive risk factor management in the stenting and aggressive medical management for prevention of recurrent stroke in intracranial stenosis (SAMMPRIS) trial", Circ Cardiovasc Qual Outcomes, 5, pp.e51~e60 (2012)
44. Turan TN, "Relationship between risk factor control and vascular events in the SAMMPRIS trial", Neurology, 88, pp.379~385 (2017)
45. Waters MF, "Factors associated with recurrent ischemic stroke in the medical group of the SAMMPRIS Trial", JAMA Neurol, 73, pp.308~315 (2016)
46. Messerli FH, "Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?", Ann Intern Med, 144, pp.884~893 (2006)
47. Sleight P, "Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study", J Hypertens, 27, pp.1360~1369 (2009)
48. ACCORD Study Group, "Effects of intensive bloodpressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
49. Bangalore S, "Blood pressure targets in subjects with type 2 diabetes mellitus", impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials, 2011, pp.123, 2799~2810
50. Fan F, "Optimal systolic blood pressure levels for primary prevention of stroke in general hypertensive adults: findings from the CSPPT (China stroke primary prevention trial)", Hypertension, 69, pp.697~704 (2017)
51. Lee M, "Does achieving an intensive versus usual blood pressure level prevent stroke?", Ann Neurol, 71, pp.133~140 (2012)
52. Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and metaanalysis", Lancet, 387, pp.435~443 (2016)
53. SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
54. Perkovic V, "Redefining blood-pressure targets--SPRINT starts the marathon", N Engl J Med, 373, pp.2175~2178 (2015)
55. Lonn EM, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2009~2020 (2016)
56. Arima H, "Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial", J Hypertens, 24, pp.1201~1208 (2006)
57. Turan TN, "Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis", Circulation, 115, pp.2969~2975 (2007)
58. Powers WJ, "Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia", Neurology, 82, pp.1027~1032 (2014)
59. Amin-Hanjani S, "Higher stroke risk with lower blood pressure in hemodynamic vertebrobasilar disease: analysis from the VERiTAS study", J Stroke Cerebrovasc Dis, 26, pp.403~410 (2017)
60. SPS3 Study Group, "Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial", Lancet, 382, pp.507~515 (2013)
61. Kernan WN, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
62. Qureshi AI, "Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States", Am J Emerg Med, 25, pp.32~38 (2007)
63. Leonardi-Bee J, "Blood pressure and clinical outcomes in the international stroke trial", Stroke, 33, pp.1315~1320 (2002)
64. Schrader J, "The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors", Stroke, 34, pp.1699~1703 (2003)
65. Potter JF, "Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial", Lancet Neurol, 8, pp.48~56 (2009)
66. Sandset EC, "The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial", Lancet, 377, pp.741~750 (2011)
67. Oh MS, "Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open-label, blinded-end-point trial", Int J Stroke, 10, pp.745~751 (2015)
68. Jusufovic M, "Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis", Int J Stroke, 10, pp.354~359 (2015)
69. He J, "Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial", JAMA, 311, pp.479~489 (2014)
70. Lee M, "Effect of blood pressure lowering in early ischemic stroke:meta-analysis", Stroke, 46, pp.1883~1889 (2015)
71. Jauch EC, "Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 870~947
72. TIMI Study Group, "Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial", N Engl J Med, 320, pp.618~627 (1989)
73. GUSTO investigators, "An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction", N Engl J Med, 329, pp.673~682 (1993)
74. Wahlgren N, "Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: safe Implementation of thrombolysis in stroke-monitoring study (SITS-MOST)", Stroke, 39, pp.3316~3322 (2008)
75. Ahmed N, "Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from safe implementation of thrombolysis in stroke-international stroke thrombolysis register (SITS-ISTR)", Stroke, 40, pp.2442~2449 (2009)
76. Huang Y, "Rationale, design, and progress of the enhanced control of hypertension and thrombolysis stroke study (ENCHANTED)trial: an international multicenter 2 x 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment", Int J Stroke, 10, pp.778~788 (2015)
77. Martins AI, "Recanalization modulates association between blood pressure and functional outcome in acute ischemic stroke", Stroke, 47, pp.1571~1576 (2016)
78. Hemphill JC 3rd, "Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2015, pp.46, 2032~2060
79. Steiner T, "European stroke organisation (ESO)guidelines for the management of spontaneous intracerebral hemorrhage", Int J Stroke, 9, pp.840~855 (2014)
80. Anderson CS, "Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial", Lancet Neurol, 7, pp.391~399 (2008)
81. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators, "Antihypertensive treatment of acute cerebral hemorrhage", Crit Care Med, 38, pp.637~648 (2010)
82. Anderson CS, "Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage", N Engl J Med, 368, pp.2355~2365 (2013)
83. Qureshi AI, "Intensive blood-pressure lowering in patients with acute cerebral hemorrhage", N Engl J Med, 375, pp.1033~1043 (2016)

관련 논문AI추천